John Quisel Sells 33,000 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the sale, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. The trade was a 12.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $80.32 on Thursday. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $75.39 and a 200-day simple moving average of $69.91. The company has a market cap of $307.63 million, a PE ratio of -12.21 and a beta of 1.00. Disc Medicine, Inc. has a 12-month low of $40.00 and a 12-month high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. On average, equities research analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Institutional Trading of Disc Medicine

Institutional investors have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Disc Medicine by 2.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 114,109 shares of the company’s stock valued at $8,346,000 after buying an additional 3,219 shares in the last quarter. Wellington Management Group LLP raised its position in Disc Medicine by 0.3% in the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company’s stock worth $127,362,000 after acquiring an additional 5,975 shares in the last quarter. Palo Alto Investors LP acquired a new stake in Disc Medicine in the 2nd quarter valued at about $30,473,488,000. Capstone Investment Advisors LLC acquired a new stake in Disc Medicine in the 2nd quarter valued at about $245,000. Finally, Bank of America Corp DE bought a new position in shares of Disc Medicine during the 2nd quarter valued at about $9,882,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analysts Set New Price Targets

IRON has been the subject of several recent analyst reports. Morgan Stanley reissued an “overweight” rating and issued a $90.00 price target on shares of Disc Medicine in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. HC Wainwright raised their target price on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Wedbush restated an “outperform” rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $106.50.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.